ACS Medicinal Chemistry Letters
Letter
and functional diversity of native brain neuronal nicotinic receptors.
Biochem. Pharmacol. 2009, 78, 703−711.
In summary, we describe the synthesis, pharmacological
evaluation, and behavioral characterization of some 5-cyclo-
propane-bearing pyridyldiazabicyclo[3.3.0]octanes as nAChR
ligands. All tested ligands with the exception of compound 10
showed excellent binding affinities for both α4β2- and α4β2*-
nAChRs from the rat (Ki values ranging from 0.4 to 4.1 nM)
and poor affinity for rat α3β4-nAChRs (Ki >2400 nM). In
functional studies, these ligands acted as potent agonists at
human α4β2-nAChRs and were inactive at both ganglionic
α3β4*- or muscle-type α1β1γδ-nAChRs. In this series, the
fluoro-analogue 15 was found to possess subnanomolar binding
affinity, a 1550-fold selectivity for α4β2- versus α3β4-nAChRs,
as well as good agonist efficacy in the functional studies.
Compound 15 achieves a brain concentration of ∼0.70 μM at
30 min, and this is over 400-times more than its binding affinity
at the α4β2-nAChR. Compound 15 was found to display
antidepressant-like properties in the mouse forced-swim test.
The above data support our hypothesis that the incorporation
of the cyclopropane side chain at the 5-position of the
pyridyldiazabicyclo[3.3.0]octanes would improve subtype
selectivity for α4β2- over α3β4-nAChRs when compared to
the parent compound 4, thus implying that the nature of the
substitution at the position 5 plays a vital role in attenuating
possible side effects associated with ganglionic α3β4*-nAChRs.
These potent and selective nAChR ligands produced
antidepressant/anxiolytic-like properties in the SmartCube
test, and thus, they may serve as chemical probes in further
exploring various aspects of nicotinic receptor function related
to mood disorders.
(2) Gotti, C.; Riganti, L.; Vailanti, S.; Clementi, F. Brain neuronal
nicotinic receptors as new targets for drug discovery. Curr. Pharm. Des.
2006, 12, 407−428.
(3) Romanelli, M. N.; Gratteri, P.; Guandalini, L.; Martini, E.;
Bonaccini, C.; Gualtieri, F. Central nicotinic receptors: Structure,
function, ligands, and therapeutic potential. ChemMedChem 2007, 2,
746−767.
(4) Lemoine, D.; Jiang, R.; Taly, A.; Chataigneau, T.; Specht, A.;
Grutter, T. Ligand-gated ion channels: New insights into neurological
disorders and ligand recognition. Chem. Rev. 2012, 112, 6285−6318.
(5) Lee, C.-H.; Zhu, C.; Malysz, J.; Campbell, T.; Shaughnessy, T.;
Honore, P.; Polakowski, J.; Gopalakrishnan, M. Alpha 4 beta 2
neuronal nicotinic receptor positive allosteric modulation: An
approach for improving the therapeutic index of alpha 4 beta 2
nAChR agonists in pain. Biochem. Pharmacol. 2011, 82, 959−966.
(6) Meyer, M. D. Neuronal nicotinic acetylcholine receptors as a
target for the treatment of neuropathic pain. Drug Dev. Res. 2006, 67,
355−359.
(7) Arneric, S. P.; Holladay, M.; Williams, M. Neuronal nicotinic
receptors: A perspective on two decades of drug discovery research.
Biochem. Pharmacol. 2007, 74, 1092−1101.
(8) Philip, N. S.; Carpenter, L. L.; Tyrka, A. R.; Price, L. H. Nicotinic
acetylcholine receptors and depression: a review of the preclinical and
clinical literature. Psychopharmacology 2010, 212, 1−12.
(9) Wilens, T. E.; Decker, M. W. Neuronal nicotinic receptor
agonists for the treatment of attentioon-deficit/hyperactivity disorder:
Focus on cognition. Biochem. Pharmacol. 2007, 74, 1212−1223.
(10) Taly, A.; Corringer, P.-J.; Guedin, D.; Lestage, P.; Changeux, J.-
P. Nicotinic receptors: allosteric transitions and therapeutic targets in
the nervous system. Nat. Rev. Drug Discovery 2009, 8, 733−750.
(11) Coe, J. W.; Brooks, P. R.; Vetelino, M. G.; Wirtz, M. C.; Arnold,
E. P.; Huang, J. H.; Sands, S. B.; Davis, T. I.; Lebel, L. A.; Fox, C. B.;
Shrikhande, A.; Heym, J. H.; Schaeffer, E.; Rollema, H.; Lu, Y.;
Mansbach, R. S.; Chambers, L. K.; Rovetti, C. C.; Schulz, D. W.;
Tingley, F. D.; O’Neill, B. T. Varenicline: An alpha 4 beta 2 nicotinic
receptor partial agonist for smoking cessation. J. Med. Chem. 2005, 48,
3474−3477.
(12) Mihalak, K. B.; Carroll, F. I.; Luetje, C. W. Varenicline is a
partial agonist at alpha 4 beta 2 and a full agonist at alpha 7 neuronal
nicotinic receptors. Mol. Pharmacol. 2006, 70, 801−805.
(13) Rollema, H.; Guanowsky, V.; Mineur, Y. S.; Shrikhande, A.;
Coe, J. W.; Seymour, P. A.; Picciotto, M. R. Varenicline has
antidepressant-like activity in the forced swim test and augments
sertraline’s effect. Eur. J. Pharmacol. 2009, 605, 114−116.
(14) Rollema, H.; Hajos, M.; Seymour, P. A.; Kozak, R.; Majchrzak,
M. J.; Guanowsky, V.; Horner, W. E.; Chapin, D. S.; Hoffmann, W. E.;
Johnson, D. E.; McLean, S.; Freeman, J.; Williams, K. E. Preclinical
pharmacology of the alpha 4 beta 2 nAChR partial agonist varenicline
related to effects on reward, mood and cognition. Biochem. Pharmacol.
2009, 78, 813−824.
ASSOCIATED CONTENT
* Supporting Information
Experimental procedures and analytical data. This material is
■
S
AUTHOR INFORMATION
Corresponding Author
*Phone: +1-312-996-7577. Fax: +1-312-996-7107. E-mail:
■
Funding
This research was supported by Award Number
U19MH085193 from the National Institute of Mental Health.
Notes
The authors declare no competing financial interest.
ACKNOWLEDGMENTS
■
We thank the PDSP program for performing the binding
affinity assays. We thank Drs. Joel Bergman and Li-fang Yu for
their assistance in proofreading the manuscript. We thank Dr.
Afshin Ghavami of PsychoGenics Inc. for his helpful
discussions.
(15) Lummis, S. C. R.; Thompson, A. J.; Bencherif, M.; Lester, H. A.
Varenicline is a potent agonist of the human 5-hydroxytryptamine(3)
receptor. J. Pharmacol. Exp. Ther. 2011, 339, 125−131.
(16) Jorenby, D. E.; Hays, J. T.; Rigotti, N. A.; Azoulay, S.; Watsky, E.
J.; Williams, K. E.; Billing, C. B.; Gong, J.; Reeves, K. R. Efficacy of
varenicline, an alpha 4 beta 2 nicotinic acetylcholine receptor partial
agonist, vs placebo or sustained-release bupropion for smoking
cessation: A randomized controlled trial. JAMA, J. Am. Med. Assoc.
2006, 296, 56−63.
(17) Stokes, C.; Papke, R. L. Use of an alpha 3 beta 4 nicotinic
acetylcholine receptor subunit concatamer to characterize ganglionic
receptor subtypes with specific subunit composition reveals species-
specific pharmacologic properties. Neuropharmacology 2012, 63, 538−
546.
(18) Leung, L. K.; Patafio, F. M.; Rosser, W. W. Gastrointestinal
adverse effects of varenicline at maintenance dose: a meta-analysis.
BMC Clin. Pharmacol. 2011, 11, 15.
ABBREVIATIONS
■
nAChR, nicotinic acetylcholine receptor; ADHD, attention
deficit hyperactivity disorder; TFA, trifluoroacetic acid; NIMH-
PDSP, National Institute of Mental Health Psychoactive Drug
Screening Program; HS, high sensitivity; LS, low sensitivity; IP,
intraperitoneal
REFERENCES
■
(1) Gotti, C.; Clementi, F.; Fornari, A.; Gaimarri, A.; Guiducci, S.;
Manfredi, I.; Moretti, M.; Pedrazzi, P.; Pucci, L.; Zoli, M. Structural
E
dx.doi.org/10.1021/ml500129k | ACS Med. Chem. Lett. XXXX, XXX, XXX−XXX